PURPOSE: Microporous polysaccharide hemospheres (MPH) are hemostatic beads engineered from plant starch to accelerate the natural clotting cascade. The purpose of this report is to detail our initial experience with MPH as a topical hemostatic agent during robot-assisted radical prostatectomy (RARP). METHODS: We examined a single surgeon series of 30 consecutive RARP's dividing patients into MPH or non-MPH groups. The last ten procedures utilized the MPH, which were matched 1:2 to non-MPH procedures for comparison. Nerve-sparing procedures were performed when clinically indicated and all done athermally. All demographic data, length of operation, margin status, blood loss, change in hemoglobin, and need for blood transfusion were prospectively collected and analyzed. RESULTS: The baseline characteristics were the same. The post-operative decrease in hemoglobin was less in the MPH group (1.8 g/dL MPH group vs. 3.2 g/dL non-MPH). One patient in each group required a blood transfusion. CONCLUSIONS: These preliminary findings support the role for MPH as a potential hemostatic agent during athermal nerve-sparing RARP.
PURPOSE: Microporous polysaccharide hemospheres (MPH) are hemostatic beads engineered from plant starch to accelerate the natural clotting cascade. The purpose of this report is to detail our initial experience with MPH as a topical hemostatic agent during robot-assisted radical prostatectomy (RARP). METHODS: We examined a single surgeon series of 30 consecutive RARP's dividing patients into MPH or non-MPH groups. The last ten procedures utilized the MPH, which were matched 1:2 to non-MPH procedures for comparison. Nerve-sparing procedures were performed when clinically indicated and all done athermally. All demographic data, length of operation, margin status, blood loss, change in hemoglobin, and need for blood transfusion were prospectively collected and analyzed. RESULTS: The baseline characteristics were the same. The post-operative decrease in hemoglobin was less in the MPH group (1.8 g/dL MPH group vs. 3.2 g/dL non-MPH). One patient in each group required a blood transfusion. CONCLUSIONS: These preliminary findings support the role for MPH as a potential hemostatic agent during athermal nerve-sparing RARP.
Authors: Francesco Montorsi; Andrea Salonia; Nazareno Suardi; Andrea Gallina; Giuseppe Zanni; Alberto Briganti; Federico Deho'; Richard Naspro; Elena Farina; Patrizio Rigatti Journal: Eur Urol Date: 2005-09-27 Impact factor: 20.096
Authors: Yakup Kordan; Daniel A Barocas; Hernan O Altamar; Peter E Clark; Sam S Chang; Rodney Davis; S Duke Herrell; Roxy Baumgartner; Vineet Mishra; Robert C Chan; Joseph A Smith; Michael S Cookson Journal: BJU Int Date: 2010-02-11 Impact factor: 5.588
Authors: James K Wright; John Kalns; Edward A Wolf; Frederick Traweek; Stacy Schwarz; CleAnn K Loeffler; William Snyder; Loudon D Yantis; Jeffrey Eggers Journal: J Trauma Date: 2004-08
Authors: Myron Schwartz; Juan Madariaga; Ryutiao Hirose; Timothy R Shaver; Linda Sher; Ravi Chari; John O Colonna; Nigel Heaton; Darius Mirza; Reid Adams; Myrddin Rees; David Lloyd Journal: Arch Surg Date: 2004-11
Authors: Brian A Bruckner; Lance N Blau; Limael Rodriguez; Erik E Suarez; Uy Q Ngo; Michael J Reardon; Matthias Loebe Journal: J Cardiothorac Surg Date: 2014-08-02 Impact factor: 1.637